Industry leader and multi-omics pioneer joins leadership team to advance AI-driven solutions

BioLizard has appointed Dr. Alexander Scheer as Chief Scientific Officer, adding 25+ years of translational R&D leadership across biotech and pharma. He will help scale BioLizard’s multi-omics and AI-driven strategy, strengthening work in biomarkers, precision medicine, and therapeutic innovation.

Gent, Belgium – 17th November, 2025.

BioLizard, a leader in multi-omics integration and AI-powered biopharma analytics, is pleased to announce the appointment of Dr. Alexander Scheer as Chief Scientific Officer (CSO). Dr. Scheer is a highly respected R&D executive with a track record of advancing therapies from discovery to clinical proof-of-concept, bringing over 25 years of leadership across biotech, pharma, and translational research. His appointment marks a significant step in scaling BioLizard’s scientific strategy and impact across biomarker discovery, precision medicine, and AI-driven therapeutic innovation.

Dr. Scheer has delivered multiple scientific and strategic milestones throughout his career, including:

  • Driving oncology and immuno-oncology programs through IND and into clinical development, including biologics and first-in-class small molecules.
  • Leading CasInvent Pharma as CEO/CSO, shaping its scientific and corporate strategy and securing strategic partnerships and financing.
  • Serving as CSO of Aelin Therapeutics, where he contributed to advancing groundbreaking Pept-in® technology and expanding the pipeline into multiple therapeutic areas.
  • CSO at Erytech Pharma, Head of Research at Pierre Fabre, and senior leadership positions at Merck and Serono, overseeing multi-site research organisations and international scientific collaborations.

He holds an MSc in Organic Chemistry from the University of Göttingen and a PhD from the German Cancer Research Centre (DKFZ) in Heidelberg, Germany.

“We are honoured to welcome Alexander to BioLizard,” said Liesbeth Ceelen, CEO. “His exceptional track record in translational R&D and pipeline development will elevate our multi-omics and AI-driven biomarker platforms. By harnessing his scientific vision, we strengthen our commitment to develop solutions that measurably improve patient outcomes.”

Dr. Scheer commented:

“Joining BioLizard at this pivotal stage of growth is truly exciting. I look forward to collaborating with this talented team to unlock the full power of multi-omics, bioinformatics, and machine learning, transforming biological complexity into actionable insights for customers and patients.”

About BioLizard

BioLizard is a dynamic, customer-centric tech-enabled biopharma services company specialising in multi-omics data integration, advanced analytics, and AI-enabled biological modelling. Serving biotech and pharmaceutical clients, BioLizard delivers end-to-end solutions, from raw data to impactful clinical insights and accelerated pipeline development. Strategic partnerships and a forward-looking mission position BioLizard as an emerging leader in European tech-enabled life sciences innovation.

How spatial biology improves clinical trial success in oncology

How spatial biology improves clinical trial success in oncology

Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.

Why bioinformatics workflows require experienced software engineers

Bioinformatics pipelines break for the smallest reasons: package updates, shifting dependencies, or “it only works on my machine.” This post explains why experienced software engineers and DevOps practices (Git, CI/CD, IaC) are essential to keep workflows reproducible, stable, and scalable.